Taho Pharmaceuticals Ltd. (TPEX:6467)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
124.50
+1.00 (0.81%)
At close: Feb 11, 2026
Market Cap6.40B +152.9%
Revenue (ttm)7.78M
Net Income-165.97M
EPS-3.37
Shares Out51.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume140,651
Average Volume348,166
Open122.00
Previous Close123.50
Day's Range120.00 - 125.00
52-Week Range43.15 - 208.50
Beta-59.16
RSI42.36
Earnings DateApr 23, 2026

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. Its pipeline includes TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting; and TAH3311 Apixaban oral film and TAH3341 Apixaban oral extend release films for patients with Dysphagia. The company also develops TAH2211 Buprenorphine/Naloxone sublingual film and TAH2231 Naloxone Buccal film for Opioid overdose; TAH9922 Atomoxetine oral liquid an... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6467
Full Company Profile

Financial Performance

Financial Statements